Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Target Cut by Citigroup

Arrowhead Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Citigroup cut Arrowhead Pharmaceuticals’ price target from $108 to $105 but maintained its Buy rating; the new target implies 144.88% upside from the share price cited in the report.
  • Analyst views are broadly positive but mixed: MarketBeat’s consensus is “Moderate Buy,” with an average target of $98.71, while firms’ individual targets and ratings vary.
  • Shares traded at $42.88 on Tuesday, down $1.33, and were well below their 52-week high of $95.49.
  • Five stocks to consider instead of Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) had its price objective decreased by Citigroup from $108.00 to $105.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the biotechnology company's stock. Citigroup's target price would suggest a potential upside of 144.88% from the company's current price.

Several other research firms have also recently commented on ARWR. B. Riley Financial raised their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Morgan Stanley upped their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Stifel Nicolaus decreased their price objective on shares of Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a "buy" rating for the company in a report on Friday. Royal Bank Of Canada reiterated an "outperform" rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $98.71.

Get Our Latest Stock Analysis on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR traded down $1.33 during trading hours on Tuesday, hitting $42.88. The stock had a trading volume of 504,195 shares, compared to its average volume of 2,250,039. Arrowhead Pharmaceuticals has a 1-year low of $37.06 and a 1-year high of $95.49. The firm has a market capitalization of $6.04 billion, a price-to-earnings ratio of -8.41 and a beta of 1.34. The stock's fifty day simple moving average is $62.48 and its 200 day simple moving average is $70.90. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Carolina Wealth Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 154 shares during the last quarter. Optiver Holding B.V. grew its holdings in shares of Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock worth $26,000 after acquiring an additional 186 shares during the last quarter. Harbour Investments Inc. raised its position in shares of Arrowhead Pharmaceuticals by 44.4% during the third quarter. Harbour Investments Inc. now owns 754 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 232 shares during the period. Versant Capital Management Inc raised its position in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 248 shares during the period. Finally, QRG Capital Management Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 7.1% during the second quarter. QRG Capital Management Inc. now owns 4,810 shares of the biotechnology company's stock valued at $392,000 after purchasing an additional 317 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company's research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Read More

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines